ID

44994

Description

Principal Investigator: Dan Roden, MD, Vanderbilt University Medical Center, Nashville, TN, USA MeSH: Hypertension https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000297 The **e**lectronic **M**edical **R**ecords and **Ge**nomics (eMERGE) Network is a consortium of five participating sites (Group Health Seattle, Marshfield Clinic, Mayo Clinic, Northwestern University, and Vanderbilt University) funded by the NHGRI to investigate the use of electronic medical record systems for genomic research. The goal of eMERGE is to conduct genome-wide association studies in approximately 19,000 individuals using EMR-derived phenotypes and DNA from linked Biorepositories. Using electronic phenotyping methods, the consortium used DNA samples from all participating sites to explore the genetic determinants of resistant hypertension. Treatment resistant hypertension is a common health problem in the clinical setting. A basic definition of resistant hypertension included subjects with uncontrolled blood pressure despite use of three antihypertensive medications or subjects requiring four or more medications to maintain control. Other conditions, such as secondary causes of hypertension, were exclusions. Site and participants include: *Vanderbilt University*: BioVU, Vanderbilt's DNA databank, is an enabling resource for exploration of the relationships among genetic variation, disease susceptibility, and variable drug responses, and represents a key first step in moving the emerging sciences of genomics and pharmacogenomics from research tools to clinical practice. BioVU acquires DNA from discarded blood samples collected from routine patient care. The biobank is linked to de-identified clinical data extracted from Vanderbilt's EMR, which forms the basis for phenotype definitions used in genotype-phenotype correlations. *Marshfield Clinic*: The Marshfield Clinic Personalized Medicine Research Project is a population-based biobank in central Wisconsin with more than 20,000 adult subjects who provided written, informed consent to access their medical records and provided a blood sample from which DNA was extracted and plasma and serum stored. In addition to an average of 30 years of medical history data, a questionnaire about environmental exposures, including a detailed food frequency questionnaire, is available to facilitate gene/environment studies. *Northwestern University*: The NUgene Project is a repository with longitudinal medical information from participating patients at affiliated hospitals and outpatient clinics from the Northwestern University Medical Center. Participants' DNA samples are coupled with data from a self-reported questionnaire and continuously updated data from our Electronic Medical Record (EMR) representing actual clinical care events. Northwestern has a state-of-the art, comprehensive inpatient and outpatient EMR system of over 2 million patients. NUgene has broad access to participant data for all outpatient visits as well as inpatient data via a consolidated data warehouse. NUgene participants consent to distribution and use of their coded DNA samples and data for a broad range of genetic research by third-party investigators. *Group Health(GH)/University of Washington (UW)*: Aging and Dementia eMERGE study biorepository leverages rich population-based longitudinal data from both electronic medical records and in-depth research data to explore genome wide associations. Participants include Seattle-area members of GH (a large integrated health care system in Washington State) consented and enrolled in 1) the UW Alzheimer's Disease Patient Registry (ADPR) and 2) the Adult Changes in Thought (ACT) study. The ADPR (PI: Eric B. Larson; NIH/NIA U01 AG 006781) is a population-based registry of incident dementia cases designed to identify all new Alzheimer's Disease cases within GH from 1987 to 1996. Medical history, physical, laboratory testing, and neuropsychological testing were performed on all consenting potential cases for determination of dementia status by a consensus conference. The study base of the ADPR population was stable with an attrition rate of less than 1%/year. The ACT study (PI: Eric B. Larson; NIH/NIA U01 AG 006781) is an ongoing community-based cohort study of aging and dementia. The original cohort of 2,581 randomly selected dementia-free members age 65 and older was enrolled in 1994-1996 and expanded by 811 in 2000-2002. Continuous enrollment to maintain a cohort of 2,000 dementia free persons began in 2005. Participants receive biennial assessment including cognitive status determination. The ACT sub-sample is stable; for the original cohort, median enrollment in GH was 19 years prior to joining the ACT study, and 85% of the cohort has ≥ 10 years of GH enrollment. DNA for the ADPR participants were obtained through a companion study, Genetic Differences in Cases and Controls (PI: Walter Kukull; NIH/NIA R01 AG007584). DNA obtained through both studies were extracted from blood using Gentra Systems Puregene methods. DNA concentration is determined by UV optical density. All samples are checked for quality by 260/280 ratio. For long-term storage, samples are aliquoted and stored at -70°C. *Mayo Clinic*: The Mayo biobank is a disease-specific biobank for vascular diseases including peripheral arterial disease (PAD). PAD patients were identified from individuals referred to the non-invasive vascular laboratory for lower extremity arterial evaluation. Since 1997, laboratory findings have been recorded into an electronic database employing an in-house software package for data archiving and retrieval; this data becomes part of the Mayo EMR. Patients referred to the center with suspected PAD undergo a comprehensive non-invasive evaluation including the ankle-brachial index (ABI) - the ratio of blood pressure measured in the upper arms divided by blood pressure measured at the ankles. Controls subjects are identified from patients referred to the Cardiovascular Health Clinic for stress ECG. The prevalence of PAD in patients with normal exercise capacity who do not have inducible ischemia on the stress ECG, was 1%. Data regarding risk factors for atherosclerosis such as diabetes, dyslipidemia, hypertension, and smoking are ascertained from the EMR.

Link

https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000297

Keywords

  1. 6/23/22 6/23/22 - Dr. Christian Niklas
  2. 10/12/22 10/12/22 - Adrian Schulz
Copyright Holder

Dan Roden, MD, Vanderbilt University Medical Center, Nashville, TN, USA

Uploaded on

June 23, 2022

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

dbGaP phs000297 eMERGE Network Study of Resistant Hypertension

Resistant Hypertension - Sample - Subject Mapping

pht002392
Description

pht002392

Subject ID
Description

subjid

Data type

string

Alias
UMLS CUI [1,1]
C2348585
Sample ID
Description

sampid

Data type

string

Alias
UMLS CUI [1,1]
C1299222
The Illumina chip used to genotype the sample.
Description

chip

Data type

text

Alias
UMLS CUI [1,1]
C4687476
UMLS CUI [1,2]
C0600596
UMLS CUI [1,3]
C0457083
Some samples were pulled from previously genotyped studies and other samples were genotyped as part of a focused resistant hypertension study.
Description

newlygenotyped

Data type

text

Alias
UMLS CUI [1,1]
C1285573
UMLS CUI [1,2]
C0745130
UMLS CUI [2,1]
C1285573
UMLS CUI [2,2]
C3840932
Subject's sample use
Description

SAMPLE_USE

Data type

text

Alias
UMLS CUI [1,1]
C0370003
UMLS CUI [1,2]
C0457083

Similar models

Resistant Hypertension - Sample - Subject Mapping

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
pht002392
subjid
Item
Subject ID
string
C2348585 (UMLS CUI [1,1])
sampid
Item
Sample ID
string
C1299222 (UMLS CUI [1,1])
Item
The Illumina chip used to genotype the sample.
text
C4687476 (UMLS CUI [1,1])
C0600596 (UMLS CUI [1,2])
C0457083 (UMLS CUI [1,3])
Code List
The Illumina chip used to genotype the sample.
CL Item
Illumina660 (660)
C4687476 (UMLS CUI [1,1])
CL Item
Illumina1M (1M)
C4687476 (UMLS CUI [1,1])
Item
Some samples were pulled from previously genotyped studies and other samples were genotyped as part of a focused resistant hypertension study.
text
C1285573 (UMLS CUI [1,1])
C0745130 (UMLS CUI [1,2])
C1285573 (UMLS CUI [2,1])
C3840932 (UMLS CUI [2,2])
Code List
Some samples were pulled from previously genotyped studies and other samples were genotyped as part of a focused resistant hypertension study.
CL Item
Previously genotyped as part of another study (N)
CL Item
Newly genotyped (Y)
Item
Subject's sample use
text
C0370003 (UMLS CUI [1,1])
C0457083 (UMLS CUI [1,2])
Code List
Subject's sample use
CL Item
SNP genotypes obtained using standard or custom microarrays (SNP_Array)

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial